NYSE:RMD - ResMed Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $237.40
  • Forecasted Upside: -0.89 %
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$239.52
▲ +2.08 (0.88%)

This chart shows the closing price for RMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ResMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RMD

Analyst Price Target is $237.40
▼ -0.89% Downside Potential
This price target is based on 12 analysts offering 12 month price targets for ResMed in the last 3 months. The average price target is $237.40, with a high forecast of $270.00 and a low forecast of $210.00. The average price target represents a -0.89% upside from the last price of $239.52.

This chart shows the closing price for RMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in ResMed. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 1 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/21/2021Robert W. BairdInitiated CoverageNeutralLow
6/21/2021Needham & Company LLCBoost Price TargetPositive ➝ Buy$229.00 ➝ $267.00Low
6/16/2021Bank of AmericaDowngradeNeutral ➝ Underperform$216.00 ➝ $221.00High
6/15/2021OppenheimerBoost Price TargetOutperform$240.00 ➝ $270.00High
6/14/2021Needham & Company LLCInitiated CoverageBuy$229.00High
6/9/2021CLSAUpgradeSell ➝ OutperformLow
5/21/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$206.00 ➝ $219.00Low
5/11/2021CitigroupUpgradeNeutral ➝ BuyLow
5/11/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgradeNeutral ➝ BuyHigh
4/30/2021CitigroupDowngradeBuy ➝ NeutralHigh
4/30/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngradeBuy ➝ NeutralHigh
3/16/2021Needham & Company LLCUpgradeHold ➝ Buy$229.00Low
1/29/2021Needham & Company LLCReiterated RatingHoldHigh
11/2/2020UBS GroupUpgradeNeutral ➝ Buy$210.00High
10/30/2020Credit Suisse GroupUpgradeNeutral ➝ OutperformHigh
10/30/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$165.00Medium
10/27/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$186.00High
8/6/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightMedium
8/6/2020OppenheimerBoost Price Target$200.00 ➝ $210.00Medium
8/6/2020The Goldman Sachs GroupDowngradeBuy ➝ NeutralHigh
8/6/2020Needham & Company LLCReiterated RatingHoldHigh
8/5/2020OppenheimerInitiated CoverageBuy$212.00High
8/3/2020Bank of AmericaDowngradeBuy ➝ UnderperformLow
6/17/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$176.00Low
5/1/2020JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
4/30/2020Needham & Company LLCInitiated CoverageHoldHigh
4/30/2020OppenheimerUpgradeMarket Perform ➝ Outperform$200.00High
3/26/2020Credit Suisse GroupDowngradeOutperform ➝ NeutralHigh
3/24/2020William BlairReiterated RatingBuyLow
2/18/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$165.00Low
2/3/2020CLSAInitiated CoverageUnderperformHigh
1/31/2020UBS GroupDowngradeBuy ➝ Neutral$174.00High
1/9/2020OppenheimerInitiated CoverageHoldLow
11/22/2019KeyCorpInitiated CoverageSector Weight ➝ Sector WeightLow
10/25/2019Needham & Company LLCReiterated RatingHoldHigh
10/18/2019Needham & Company LLCReiterated RatingHoldLow
7/29/2019UBS GroupUpgradeNeutral ➝ Buy$122.00 ➝ $140.00Medium
7/29/2019The Goldman Sachs GroupUpgradeNeutral ➝ BuyMedium
7/16/2019UBS GroupDowngradeBuy ➝ NeutralLow
5/6/2019UBS GroupUpgradeNeutral ➝ Buy$109.00 ➝ $119.00Low
4/18/2019JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$95.00Low
3/20/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyLow
1/28/2019BMO Capital MarketsLower Price TargetOutperform ➝ Positive$120.00High
1/25/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$99.60High
1/25/2019The Goldman Sachs GroupDowngradeBuy ➝ NeutralHigh
1/23/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldLow
12/10/2018BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$109.00 ➝ $127.00Medium
10/26/2018BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$107.00 ➝ $109.00N/A
10/26/2018Credit Suisse GroupUpgradeNeutral ➝ OutperformHigh
7/1/2018The Goldman Sachs GroupInitiated CoverageBuyLow
4/24/2018UBS GroupDowngradeBuy ➝ NeutralMedium
4/16/2018William BlairReiterated RatingOutperformLow
4/4/2018CitigroupDowngradeBuy ➝ NeutralMedium
3/7/2018Needham & Company LLCReiterated RatingHoldMedium
1/23/2018Northland SecuritiesUpgradeUnder Perform ➝ Market PerformHigh
1/23/2018MacquarieDowngradeNeutral ➝ SellHigh
1/23/2018BMO Capital MarketsBoost Price TargetMarket Perform$90.00High
1/23/2018Needham & Company LLCUpgradeUnderperform ➝ HoldHigh
12/12/2017BMO Capital MarketsBoost Price TargetMarket Perform$82.00Low
10/30/2017JPMorgan Chase & Co.Boost Price TargetOverweight$72.00 ➝ $73.00N/A
10/27/2017BMO Capital MarketsBoost Price TargetMarket Perform$70.00 ➝ $74.00N/A
10/27/2017BarclaysBoost Price TargetUnderweight$68.00 ➝ $70.00N/A
10/27/2017Northland SecuritiesReiterated RatingSell$55.00N/A
10/27/2017Needham & Company LLCReiterated RatingSellN/A
10/12/2017Jefferies Financial GroupReiterated RatingSell$56.00N/A
9/25/2017BarclaysBoost Price TargetUnderweight ➝ Underweight$65.00 ➝ $68.00Low
9/8/2017Needham & Company LLCReiterated RatingSellLow
8/8/2017Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
8/2/2017BMO Capital MarketsBoost Price TargetMarket Perform$61.00 ➝ $70.00Medium
8/2/2017Needham & Company LLCReiterated RatingSellHigh
8/2/2017CitigroupUpgradeNeutral ➝ BuyHigh
8/2/2017Credit Suisse GroupDowngradeOutperform ➝ NeutralHigh
8/2/2017Bank of AmericaDowngradeBuy ➝ NeutralHigh
5/12/2017BMO Capital MarketsReiterated RatingHoldLow
4/28/2017CitigroupDowngradeBuy ➝ NeutralHigh
4/28/2017Jefferies Financial GroupReiterated RatingSell$56.00Low
4/20/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$72.00 ➝ $71.00Medium
4/13/2017William BlairReiterated RatingOutperformLow
2/6/2017Canaccord GenuityReiterated RatingHold$59.00N/A
1/24/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$72.00N/A
1/24/2017Needham & Company LLCReiterated RatingSellN/A
1/24/2017BMO Capital MarketsReiterated RatingHold$61.00N/A
1/24/2017BarclaysBoost Price TargetUnderweight$55.00 ➝ $60.00N/A
1/23/2017Canaccord GenuityReiterated RatingHold$55.00 ➝ $59.00N/A
10/26/2016Jefferies Financial GroupLower Price Target$56.00N/A
10/22/2016Jefferies Financial GroupReiterated RatingUnderperform$58.00N/A
10/4/2016JPMorgan Chase & Co.Initiated CoverageNeutral$64.00N/A
9/29/2016Bank of AmericaUpgradeNeutral ➝ Buy$89.00 ➝ $72.00N/A
9/19/2016JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralN/A
9/12/2016Needham & Company LLCReiterated RatingSellN/A
8/30/2016Needham & Company LLCReiterated RatingUnderperformN/A
8/29/2016Northland SecuritiesSet Price TargetSell$50.00N/A
8/26/2016BarclaysReiterated RatingUnderweight$55.00N/A
8/23/2016Jefferies Financial GroupDowngradeHold ➝ Underperform$60.00 ➝ $58.00N/A
7/29/2016Jefferies Financial GroupBoost Price TargetHold$56.00 ➝ $60.00N/A
7/25/2016Canaccord GenuityReiterated RatingHold$57.00N/A
7/10/2016Bank of AmericaReiterated RatingHold$65.00N/A
6/27/2016Needham & Company LLCDowngradeHold ➝ UnderperformN/A
(Data available from 6/21/2016 forward)
ResMed logo
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $239.52
Low: $235.90
High: $239.99

50 Day Range

MA: $206.33
Low: $187.97
High: $240.46

52 Week Range

Now: $239.52
Low: $165.72
High: $242.50

Volume

447,301 shs

Average Volume

654,172 shs

Market Capitalization

$34.85 billion

P/E Ratio

76.52

Dividend Yield

0.66%

Beta

0.29

Frequently Asked Questions

What sell-side analysts currently cover shares of ResMed?

The following Wall Street sell-side analysts have issued stock ratings on ResMed in the last year: Bank of America Co., Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, CLSA, Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., The Goldman Sachs Group, Inc., UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for RMD.

What is the current price target for ResMed?

5 Wall Street analysts have set twelve-month price targets for ResMed in the last year. Their average twelve-month price target is $229.80, suggesting a possible downside of 3.2%. Oppenheimer Holdings Inc. has the highest price target set, predicting RMD will reach $270.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $210.00 for ResMed in the next year.
View the latest price targets for RMD.

What is the current consensus analyst rating for ResMed?

ResMed currently has 1 sell rating, 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RMD will outperform the market and that investors should add to their positions of ResMed.
View the latest ratings for RMD.

What other companies compete with ResMed?

How do I contact ResMed's investor relations team?

ResMed's physical mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider's listed phone number is 858-836-5000 and its investor relations email address is [email protected] The official website for ResMed is www.resmed.com.